X-linked hypophosphatemia Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight
X-linked hypophosphatemia is a hereditary renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth. Phosphate levels are low because phosphate is abnormally processed in the kidneys, which causes a loss of phosphate in the urine (phosphate wasting) and leads to soft, weak bones (rickets). XLH is usually diagnosed in childhood. Features include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is the most common form of hereditary hypophosphatemic rickets.
DelveInsight's "X
Linked Hypophosphatemia Market Insights, Epidemiology, and Market
Forecast-2030" report delivers an in-depth understanding of the X
Linked Hypophosphatemia, historical and forecasted epidemiology as well as the
X Linked Hypophosphatemia market trends in the United States, EU5 (Germany,
Spain, Italy, France, and United Kingdom) and Japan.
Some facts of X
Linked Hypophosphatemia Market Report are:
·
According to study conducted by He ́le`ne et
al., titled “Impaired quality of life in adults with X-linked hypophosphatemia
and skeletal symptoms”, the estimated prevalence of X-linked hypophosphatemia
was 4.8 per 100,000.
·
As per Endocrine Society, the Food and Drug
Administration (FDA) estimates that XLH affects about 3,000 children and 12,000
adults in the United States
·
According to Phosphodiabetes E.V. Netzwerk
Information Austausch, estimates that X-linked hypophosphatemia (XLH) is the
most common form of vitamin D-resistant rickets and, with a prevalence of 4.8
cases per 100,000 individuals, is considered a rare disease.
·
The study by Riancho et al., titled
“Osteomalacia and rickets” estimates that the prevalence of Hypophosphatemic
rickets linked to the X chromosome due to a mutation in the PHEX gene is around
5 per 100,000.
View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
Request for Sample
Report: https://www.delveinsight.com/sample-request/x-linked-hypophosphatemia-market
Scope of X
Linked Hypophosphatemia Market Report are:
- The
report covers the descriptive overview of X Linked Hypophosphatemia,
explaining its causes, signs and symptoms, pathophysiology, diagnosis and
currently available therapies
- Comprehensive
insight has been provided into the X Linked Hypophosphatemia epidemiology
and treatment in the 7MM
- Additionally,
an all-inclusive account of both the current and emerging therapies for X
Linked Hypophosphatemia are provided, along with the assessment of new
therapies, which will have an impact on the current treatment landscape
- A
detailed review of X Linked Hypophosphatemia market; historical and
forecasted is included in the report, covering drug outreach in the 7MM
- The
report provides an edge while developing business strategies, by
understanding trends shaping and driving the global X Linked
Hypophosphatemia market
View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
Some of X
Linked Hypophosphatemia Companies are:
·
Ultragenyx
·
Validus Pharmaceuticals
·
Prospec-Tany Technogene Ltd
·
Merck KGaA
·
Zeria Pharmaceutical Co., Ltd
·
Smith & Nephew
·
Narang Medical Limited
·
Eli Lilly and Company
·
F. Hoffmann-La Roche Ltd
·
And Many Others
View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
Request for Sample
Report: https://www.delveinsight.com/sample-request/x-linked-hypophosphatemia-market
X
Linked Hypophosphatemia Therapies are:
·
Burosumab
·
Crysvita
·
And Many Others
Table of Contents:
1. Key Insights
2. Executive Summary
of X Linked Hypophosphatemia
3. Competitive
Intelligence Analysis for X Linked Hypophosphatemia
4. X Linked
Hypophosphatemia: Market Overview at a Glance
4.1. X Linked Hypophosphatemia Total Market Share (%)
Distribution in 2018
4.2. X Linked Hypophosphatemia Total Market Share (%)
Distribution in 2030
5. X Linked
Hypophosphatemia: Disease Background and Overview
6. Patient Journey
7. X Linked
Hypophosphatemia Epidemiology and Patient Population
8. Treatment
Algorithm, Current Treatment, and Medical Practices
8.1. X Linked Hypophosphatemia Treatment and Management
8.2. X Linked Hypophosphatemia Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of
X Linked Hypophosphatemia Treatment
11. Marketed
Products
List to be continued
in report
12. Emerging
Therapies
List to be continued
in report
13. X Linked
Hypophosphatemia: Seven Major Market Analysis
14. Attribute
analysis
15. 7MM: Market
Outlook
16. Access and
Reimbursement Overview of X Linked Hypophosphatemia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight
Capabilities
22. Disclaimer
Some of Newly Launched Report:
·
Neuromodulation
Devices market
·
Neurostimulation
Devices market
·
Hernia
repair devices market
About Delveinsight:
DelveInsight Business Research is a leading Market
Research, and Business Consultant focused purely on Healthcare. It
helps pharma companies by providing them with end-to-end services to solve
their business problems.
Get hold of all the Pharma and healthcare market research
reports on our market research subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business
Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Comments
Post a Comment